Evidence map›Paper›PMID 38130719›Full record

ArticleFrontiers in immunology2023

Feasibility and acceptability of undertaking postmortem studies for tuberculosis medical research in a low income country.

Gift Ahimbisibwe, Marjorie Nakibuule, Marvin Martin Ssejoba, David Oyamo, Rose Mulwana, Josephine Nabulime, Febronius Babirye, Musana Abdusalaamu Kizito, Hervé Monka Lekuya, Akello Suzan Adakun and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Tissue-specific T cell profiles inFrontiers in tuberculosis · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Gift AhimbisibweMedical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Marjorie NakibuuleMedical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Marvin Martin SsejobaMedical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
David OyamoMulago National Referral Hospital, Kampala, Uganda.
Rose MulwanaMulago National Referral Hospital, Kampala, Uganda.
Josephine NabulimeMulago National Referral Hospital, Kampala, Uganda.
Febronius BabiryeMulago National Referral Hospital, Kampala, Uganda.
Musana Abdusalaamu KizitoDepartment of Pathology, Makerere University, Kampala, Uganda.
Hervé Monka LekuyaDepartment of Surgery, Makerere University, Kampala, Uganda.
Akello Suzan AdakunMulago National Referral Hospital, Kampala, Uganda.
Daisy NalumansiMulago National Referral Hospital, Kampala, Uganda.
Stella MuryasinguraMulago National Referral Hospital, Kampala, Uganda.
Robert LukandeDepartment of Pathology, Makerere University, Kampala, Uganda.
Andrew KyazzeDivision of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda.
Joseph Baruch BalukuDivision of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda.
Irene Andia BiraroDivision of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda.
Stephen CoseMedical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Mulago Hospital · UGMakerere University · UGUganda Virus Research Institute · UGLondon School of Hygiene & Tropical Medicine · GB

Funding

IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) - SARS-CoV-2 RELATED RESEARCH75N93019C00070 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI URDAHL, KEVIN · 2019 to 2025
$86.6M
Medical Research Council MC_UU_00027/5NIAID NIH HHS 75N93019C00070
6 · The paper itself

Abstract

Introduction: If we are to break new ground in difficult-to-treat or difficult-to-vaccinate diseases (such as HIV, malaria, or tuberculosis), we must have a better understanding of the immune system at the site of infection in humans. For tuberculosis (TB), the initial site of infection is the lungs, but obtaining lung tissues from subjects suffering from TB has been limited to bronchoalveolar lavage (BAL) or sputum sampling, or surgical resection of diseased lung tissue. Methods: We examined the feasibility of undertaking a postmortem study for human tuberculosis research at Mulago National Referral Hospital in Kampala, Uganda. Results: Postmortem studies give us an opportunity to compare TB-involved and -uninvolved sites, for both diseased and non-diseased individuals. We report good acceptability of the next-of-kin to consent for their relative's tissue to be used for medical research; that postmortem and tissue processing can be undertaken within 8 hours following death; and that immune cells remain viable and functional up to 14 hours after death. Discussion: Postmortem procedures remain a valuable and essential tool both to establish cause of death, and to advance our medical and scientific understanding of infectious diseases.

Indexed as

Developing CountriesTuberculosisBronchoalveolar LavageFeasibility StudiesHumansUgandafeasibility & acceptabilitypostmortem studiesT cellstissuestuberculosis

Identifiers

PMID38130719
PMCPMC10734300
OpenAlexW4389393355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.